Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.

Abstract: The present subject matter relates to a personalized weight management program incorporating dynamic feedback control using a validated mathematical model of metabolism and weight change. In general, the subject matter provides a system for repeated monitoring of one or more parameters such as, for example, body weight, physical activity, diet, eating behavior, or various other physiological and behavioral measurements, and using the parameter(s) to calculate an objective and personalized measure of adherence to a prescribed intervention, iteratively update mathematical model parameters, and adjust the prescribed intervention based on revised model predictions. Such a dynamic feedback control methodology can improve adherence to weight management interventions and result in greater weight loss and improved weight maintenance. The present subject matter also relates to a novel, cost-effective, weight management tool that could be widely disseminated through the internet and mobile computing platforms.